Solventum Co. (NYSE:SOLV) Shares Sold by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. trimmed its position in shares of Solventum Co. (NYSE:SOLV) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,842 shares of the company’s stock after selling 1,815 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Solventum were worth $386,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Investment House LLC lifted its stake in Solventum by 111.3% during the fourth quarter. Investment House LLC now owns 76,171 shares of the company’s stock worth $5,032,000 after purchasing an additional 40,130 shares in the last quarter. Xponance Inc. lifted its stake in Solventum by 9.8% during the fourth quarter. Xponance Inc. now owns 21,014 shares of the company’s stock worth $1,388,000 after purchasing an additional 1,879 shares in the last quarter. Boston Partners acquired a new position in Solventum during the fourth quarter worth $110,378,000. Generali Asset Management SPA SGR acquired a new position in Solventum during the fourth quarter worth $659,000. Finally, Thrivent Financial for Lutherans lifted its stake in Solventum by 37.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 12,721 shares of the company’s stock worth $863,000 after purchasing an additional 3,498 shares in the last quarter.

Solventum Stock Performance

Shares of SOLV opened at $74.00 on Friday. The stock has a 50 day moving average price of $75.17 and a 200 day moving average price of $71.56. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $12.80 billion and a price-to-earnings ratio of 26.91. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Wells Fargo & Company upped their price target on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Bank of America upped their price objective on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Mizuho upped their price objective on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Piper Sandler upped their price objective on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group upped their price objective on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and a consensus price target of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.